PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB
We are a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems.
Our products and technology, which include our HiFi long-read sequencing technology, address a broad set of applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications.
Our focus is on creating some of the world's most advanced sequencing systems to provide our customers with the most complete and accurate view of genomes, transcriptomes, and epigenomes.
Last close
2.11
2026-10-23
Market cap
$655.9M
2026-06-30 share count
52-week range
1.07 - 3.44
Valuation FY2025 figures against the last close
P/S4.1x
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-1.82
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $160.0M | $154.0M | $200.5M | $128.3M | $130.5M | $78.9M | $90.9M | $78.6M | $93.5M | $90.7M |
| Cost of revenue | $114.2M | $116.7M | $147.7M | $79.3M | $71.7M | $46.3M | $56.3M | $53.5M | $58.8M | $46.6M |
| Gross profit | $45.8M | $37.3M | $52.8M | $49.0M | $58.9M | $32.6M | $34.6M | $25.1M | $34.7M | $44.2M |
| R&D | $97.3M | $134.9M | $187.2M | $193.0M | $112.9M | $64.2M | $59.6M | $62.6M | $65.3M | $67.6M |
| SG&A | $141.5M | $175.0M | $169.8M | $160.9M | $124.1M | $72.8M | $75.5M | $63.5M | $59.1M | $47.8M |
| Total operating expenses | $599.6M | $511.6M | $387.2M | $356.2M | $269.3M | $137.0M | $135.1M | $126.1M | $124.4M | $115.4M |
| Operating income | -$553.9M | -$474.3M | -$334.5M | -$307.2M | -$210.4M | -$104.4M | -$100.5M | -$101.0M | -$89.8M | -$71.2M |
| Interest expense | $7.0M | $13.4M | $14.3M | $14.7M | $12.5M | $267.0K | $2.6M | $2.4M | $2.9M | $3.2M |
| Pre-tax income | -$546.1M | -$309.5M | -$318.2M | -$314.2M | -$274.9M | $29.4M | -$84.1M | — | — | — |
| Income tax | $318.0K | $316.0K | $11.4M | $0 | $93.6M | — | — | — | — | — |
| Net income | -$546.4M | -$309.9M | -$306.7M | -$314.2M | -$181.2M | $29.4M | -$84.1M | -$102.6M | -$92.2M | -$74.4M |
| EPS, basic | -1.82 | -1.13 | -1.21 | -1.40 | -0.89 | 0.18 | -0.55 | -0.76 | — | — |
| EPS, diluted | -1.82 | -1.59 | -1.21 | -1.40 | -0.89 | 0.17 | -0.55 | -0.76 | -0.87 | -0.83 |
| Shares, diluted (wtd. avg.) | 300.0M | 288.4M | 253.6M | 224.6M | 204.1M | 175.0M | 152.5M | 135.1M | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $63.7M | $55.4M | $179.9M | $328.3M | $465.8M | $85.9M | $33.9M | $33.9M | $23.6M | $21.3M |
| Short-term investments | $215.8M | $334.6M | $451.5M | $447.2M | $583.7M | $237.2M | $19.5M | $83.5M | $46.4M | $55.2M |
| Receivables | $35.4M | $27.5M | $36.6M | $18.8M | $24.2M | $16.8M | $15.3M | $8.6M | $13.4M | $11.4M |
| Inventory | $49.3M | $58.8M | $56.7M | $50.4M | $24.6M | $14.2M | $13.3M | $17.9M | $23.1M | $15.6M |
| Total current assets | $375.1M | $495.7M | $742.0M | $852.1M | $1.10B | $355.6M | $81.0M | $131.7M | $101.6M | $109.0M |
| Property, plant and equipment | $24.1M | $30.5M | $36.4M | $41.6M | $32.5M | $24.9M | $30.1M | $34.1M | $37.9M | $14.6M |
| Goodwill | $317.8M | $317.8M | $462.3M | $410.0M | $410.0M | — | — | — | — | — |
| Other intangibles | $15.1M | $389.6M | $457.0M | $410.2M | $411.0M | — | — | — | — | — |
| Total assets | $784.1M | $1.26B | $1.75B | $1.77B | $2.01B | $414.0M | $148.0M | $170.3M | $144.1M | $137.9M |
| Accounts payable | $20.8M | $16.6M | $15.1M | $12.0M | $11.0M | $3.6M | $8.4M | $6.7M | $9.1M | $8.4M |
| Short-term debt | — | $0 | $490.0K | $1.8M | $1.6M | — | — | — | — | — |
| Total current liabilities | $72.8M | $66.3M | $95.0M | $263.3M | $71.7M | $38.5M | $49.2M | $26.9M | $28.6M | $33.8M |
| Long-term debt | — | — | — | $896.7M | $896.1M | — | $15.9M | $14.7M | $13.6M | $16.1M |
| Total liabilities | $778.7M | $753.9M | $1.04B | $1.20B | $1.22B | $78.5M | $93.1M | $56.2M | $58.0M | $53.2M |
| Retained earnings | -$2.70B | -$2.15B | -$1.84B | -$1.53B | -$1.22B | -$1.04B | -$1.07B | -$982.1M | -$879.7M | -$787.5M |
| Total equity | $5.3M | $506.6M | $701.3M | $562.9M | $791.0M | $335.5M | $54.9M | $114.1M | $86.1M | $84.7M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$111.2M | -$206.1M | -$259.2M | -$263.2M | -$111.2M | $19.5M | -$78.3M | -$66.4M | -$67.5M | -$67.9M |
| Depreciation and amortisation | $13.0M | $13.8M | $11.5M | $9.5M | $7.2M | $6.4M | $7.3M | $6.4M | $8.4M | $3.9M |
| Stock-based compensation | $41.7M | $71.0M | $72.1M | $78.6M | $73.4M | $17.5M | $16.4M | $23.2M | $20.4M | $19.6M |
| Capital expenditure | $2.7M | $6.2M | $8.8M | $16.8M | $5.9M | $1.0M | $2.8M | $1.9M | $10.4M | $8.2M |
| Investing cash flow | $115.4M | $124.0M | $4.6M | $116.1M | -$678.5M | -$219.3M | $62.0M | -$38.4M | -$1.5M | -$14.9M |
| Financing cash flow | $3.4M | -$43.0M | $108.9M | $9.6M | $1.17B | $251.8M | $26.5M | $107.2M | $68.8M | $65.9M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001299130-26-000064.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $90.7M | $93.5M | $78.6M | $90.9M | $78.9M | $130.5M | $128.3M | $200.5M | $154.0M | $160.0M |
| Gross profit | $44.2M | $34.7M | $25.1M | $34.6M | $32.6M | $58.9M | $49.0M | $52.8M | $37.3M | $45.8M |
| Net income | -$74.4M | -$92.2M | -$102.6M | -$84.1M | $29.4M | -$181.2M | -$314.2M | -$306.7M | -$309.9M | -$546.4M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Restructuring or exit costs A restructuring: layoffs, a plant closure, a business being wound down. Item 2.05
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Officer or director change Item 5.02
- Officer or director change Item 5.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Officer or director change Item 5.02
- Regulation FD disclosure Item 7.01
- Officer or director change Item 5.02
- Regulation FD disclosure Item 7.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 3826
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| A | AGILENT TECHNOLOGIES, INC. | $48.79B | 37.9x | 6.7% |
| WAT | WATERS CORP /DE/ | $44.57B | 42.2x | 7.0% |
| ILMN | ILLUMINA, INC. | $40.68B | 49.4x | -0.7% |
| MTD | METTLER TOLEDO INTERNATIONAL INC/ | $33.47B | 39.7x | 4.0% |
| RVTY | REVVITY, INC. | $17.72B | 76.7x | 3.7% |
| AVTR | Avantor, Inc. | $11.80B | — | -3.4% |
| BIO | BIO-RAD LABORATORIES, INC. | $9.89B | 13.3x | 0.7% |
| TXG | 10x Genomics, Inc. | $9.30B | — | 5.2% |